KP

Kolukki Puthanpurayil Abdulazeez

Active Director Designated Partner DIN 07134402
DIN 07134402 First appointment Mar 2025 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Mar 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Kolukki Puthanpurayil Abdulazeez

Data last updated:

Kolukki Puthanpurayil Abdulazeez is a Designated Partner at Harrow Pharmaceuticals Llp (since 2025). The company operates in Pharma.

DIN 07134402
Primary Designation Designated Partner
Industry Pharma
First Appointment 20 Mar 2025
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Designated Partner20 Mar 20252025Active

Board colleagues of Kolukki Puthanpurayil Abdulazeez

NameDINCompanyDesignation
Waqas Abdul Azeez11009232Harrow Pharmaceuticals LlpDesignated Partner

Directorship timeline

Open interactive timeline →
Harrow Pharmaceuticals Llp
Premium access

Shareholding and investment profile for Kolukki Puthanpurayil Abdulazeez

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Kolukki Puthanpurayil Abdulazeez

Kolukki Puthanpurayil Abdulazeez currently holds 1 directorship: Harrow Pharmaceuticals Llp (Designated Partner, since 20 Mar 2025).

Kolukki Puthanpurayil Abdulazeez was first appointed on 20 Mar 2025 as Designated Partner at Harrow Pharmaceuticals Llp.

The current boards of Kolukki Puthanpurayil Abdulazeez's companies include Waqas Abdul Azeez (Harrow Pharmaceuticals Llp).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available